"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT00940836","Efficacy and Safety Assessment of an Anti-Cold Preparation in the Symptomatic Treatment of Common Cold and Flu-Like Syndrome",,"Unknown status","No Results Available","Common Cold|Flu-like Syndrome","Drug: Resfenol|Drug: Placebo|Drug: Co interventional acetaminophen","Symptom improval assessed by questionnaires concerning headache, muscle ache, rhinorrhea, nasal obstruction, sneezes, cough, sore or irritated throat, hoarseness and fever, rated by patient himself in a scale from 0 to 4, being 0-absence and 4-severe.|Global duration of symptoms, assessed by the investigator through direct questioning at followup visits.|Time of return to usual activities, such as work or gym, assessed by the investigator through direct questioning at followup visits.|Use of co intervention for symptom relief during treatment, registered by the volunteer in patient diary, with day and hour of ingestion.|Improval of fever by reduction of axillary temperature to less than 38,1°C.|Adverse effect appearance during and until 7 days after treatment, assessed through patient's report in the diary or followup visit, through physical evaluation at followup and by laboratory exams.","Hospital de Clinicas de Porto Alegre","All","18 Years to 60 Years   (Adult)","Phase 3","146","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","05492","June 2009","November 2009","null","July 16, 2009","null","July 16, 2009","Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil","","https://ClinicalTrials.gov/show/NCT00940836"
2,"NCT00872430","Laxative Effectiveness of a Phytotherapeutic Tea",,"Completed","Has Results","Chronic Constipation","Other: Placebo|Other: Klein Laxative Tea","Intestinal Transit Time|Number of Patients With no Evacuation After Each Intervention Period","Hospital de Clinicas de Porto Alegre|Federal University of Rio Grande do Sul|Conselho Nacional de Desenvolvimento Científico e Tecnológico|Laboratório Klein Ltda.","All","18 Years to 55 Years   (Adult)","Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","02121","July 2002","December 2002","June 2003","March 31, 2009","March 31, 2009","June 17, 2009","Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil","","https://ClinicalTrials.gov/show/NCT00872430"
3,"NCT00845637","Effect of Eggplant Extract on Lipid Profile During Fasting and Postprandial Period",,"Completed","No Results Available","Dyslipidemia","Drug: Eggplant extract|Drug: Placebo","Lipid profile|Anthropometric measures","Hospital de Clinicas de Porto Alegre","All","Child, Adult, Older Adult","Phase 1","59","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","04004","March 2004","March 2007","March 2008","February 18, 2009","null","February 24, 2009","Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil","","https://ClinicalTrials.gov/show/NCT00845637"
4,"NCT01158326","Evaluation of Efficacy and Safety of Oral Solution Resfenol in Reducing Symptoms of Common Cold And Flu",,"Completed","No Results Available","Common Cold|Influenza","Drug: Resfenol|Other: Placebo","Reduction global symptom score (0-none, 1-weak, 2-medium, 3-strong)|Use of rescue medication for relief of symptoms, treatment compliance, improvement of foot","Hospital de Clinicas de Porto Alegre","All","12 Years to 60 Years   (Child, Adult)","Phase 3","216","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","09-542","August 2010","September 2011","November 2011","July 8, 2010","null","November 28, 2011","Hospital de Clinicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil","","https://ClinicalTrials.gov/show/NCT01158326"
5,"NCT00819065","Trial Comparing Two Commercial Formulations of Botulinum Toxin Type A in the Treatment of Spasticity",,"Completed","No Results Available","Spasticity","Drug: Botulinum toxin type A from laboratory Lanzhou|Drug: Botulinum toxin type A from laboratory Allergan","Muscle tonus reduction will be assessed by the Ashworth Scale.|Life quality will be assessed by WHOQOL-Bref, YQOL-R and Children's Life Quality assessment questionnaire, respecting the age of the patient.|Functional capability will be evaluated through the Functional Independence Measure Scale (FIM) for adults and PEDI scale for children.|Incidence, severity and duration of adverse effects of each treatment, through adverse events scale.|Perception of improvement of the symptoms by the patient himself or caregiver.","Hospital de Clinicas de Porto Alegre","All","2 Years and older   (Child, Adult, Older Adult)","Phase 3","56","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","06336","March 2009","May 2010","June 2011","January 8, 2009","null","July 7, 2011","Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil","","https://ClinicalTrials.gov/show/NCT00819065"
6,"NCT00935948","Efficacy and Safety Evaluation of the Imescard Compound Water Smartweed Ointment",,"Unknown status","No Results Available","Hemorrhoidal Disease","Drug: Imescard compound water smartweed ointment|Drug: Placebo","Improval of 50% or more in hemorrhoidal symptoms, assessed by questionnaires concerning pain, swelling, secretion and bleeding of hemorrhoids, contained in a diary that patients were instructed to fulfill daily during the treatment.|Mean scores of the symptom questionnaires mentioned above.|Life quality was assessed through the questionnaire WHOQOLbrief, at baseline and followup.|Adverse effects were assessed through a specific field in the diary and at followup during clinical evaluation.","Hospital de Clinicas de Porto Alegre","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","04497","April 2008","May 2009","null","July 9, 2009","null","July 9, 2009","Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil","","https://ClinicalTrials.gov/show/NCT00935948"
7,"NCT00861562","Clinical Efficacy and Safety Evaluation of the Drug Imescard Compound Water Smartweed Pills",,"Unknown status","No Results Available","Chronic Constipation|Hemorrhoids","Drug: Imescard water smartweed composed pills|Drug: Placebo","Reduction in colonic transit time assessed through radiologic technique.|Daily evaluation of constipation and hemorrhoidal symptoms assessed by questionnaires.|Health quality improvement assessed by WHOQOL Brief at every followup visit.|Adverse effects assessed by the investigator, blinded to the intervention, at every followup visit, through physical examination and laboratory exams.","Hospital de Clinicas de Porto Alegre","All","18 Years to 50 Years   (Adult)","Phase 3","56","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","04372","April 2008","October 2008","April 2009","March 13, 2009","null","March 13, 2009","Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil","","https://ClinicalTrials.gov/show/NCT00861562"
8,"NCT01623336","BIP48 (Peginterferon Alfa 2b 48kDa) Compared With Pegasys® (Peginterferon 2a 40kDa) for Treatment of Chronic Hepatitis C","BIP48II/III","Unknown status","No Results Available","Chronic Hepatitis C","Drug: BIP 48 (Peginterferon alfa 2b 48kDA)|Drug: Peginterferon alfa 2a 40kDA","The rate of sustained virologic response - SVR - measured by PCR at 24 weeks after treatment.|Frequency of adverse events|Virologic response at the end of treatment","The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)|Hospital de Clinicas de Porto Alegre","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2|Phase 3","740","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11/0468","January 2012","August 2016","December 2016","June 20, 2012","null","June 20, 2012","Ufrgs/Hcpa, Porto Alegre, Rio Grande do Sul, Brazil","","https://ClinicalTrials.gov/show/NCT01623336"
